**Freedom of Information Act 2000 - Request Reference FoI/23/195**
**Olarparib**

**Information Requested:**

In line with your Freedom of Information (FOI) request procedures, please find below a list of questions to be handled in accordance with this policy.

Please may you tell me how many patients were initiated with each drug and indication/form below:

Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer – TA831

Olaparib plus bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer – TA693

Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer – TA620

Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy – TA598

Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection – TA761

Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer – TA653

Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer – TA654

Acalabrutinib for treating chronic lymphocytic leukaemia – TA689

Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation – TA798

Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments – TA862

Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies – TA704

Data periods:

- Monthly from January 2022 to February 2023
- Total yearly 2020, 2021 and 2022, for each drug and indication/form above

**Response Details**

Cardiff and Vale University Health Board (the UHB) can advise that the only drug that the UHB use from the list mentioned above is Acalabrutinib.

- Monthly from January 2022 to February 2023

After considering your request, the UHB believes that Section 40 of the Freedom of Information Act 2000 applies. Due to the low numbers of individuals involved (5 or less), the UHB believes that, when considered with other information already available within the public domain, disclosure would result in the risk of individuals becoming identifiable. The data requested is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.

- Total yearly 2020, 2021 and 2022, for each drug and indication/form above

| | Total | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| **Distinct Acalabrutinib initiations.** | **30** | ***** | **12** | **10** | **5** |

Please note that Section 40 of the Freedom of Information Act 2000 has been applied where information in the above table has been replaced with an asterisk. The UHB will not provide these exact numbers due to the low numbers of individuals involved (5 or less). The UHB believes there is a potential risk of individuals being able to be identified, when considered with other information already available within the public domain, if this was disclosed. Therefore, the data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.